JP2005522432A - ニューロン成長の促進方法 - Google Patents

ニューロン成長の促進方法 Download PDF

Info

Publication number
JP2005522432A
JP2005522432A JP2003565480A JP2003565480A JP2005522432A JP 2005522432 A JP2005522432 A JP 2005522432A JP 2003565480 A JP2003565480 A JP 2003565480A JP 2003565480 A JP2003565480 A JP 2003565480A JP 2005522432 A JP2005522432 A JP 2005522432A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
methoxy
receptor antagonist
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003565480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522432A5 (cg-RX-API-DMAC7.html
Inventor
アンドリュー・フォーリー
ヘレン・ギャラガー
ジェイムズ・ハーガン
キアラン・リーガン
ニール・アップトン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202680A external-priority patent/GB0202680D0/en
Priority claimed from GB0222616A external-priority patent/GB0222616D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005522432A publication Critical patent/JP2005522432A/ja
Publication of JP2005522432A5 publication Critical patent/JP2005522432A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003565480A 2002-02-05 2003-02-04 ニューロン成長の促進方法 Withdrawn JP2005522432A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0202680A GB0202680D0 (en) 2002-02-05 2002-02-05 Novel method
GB0222616A GB0222616D0 (en) 2002-09-30 2002-09-30 Novel method
PCT/GB2003/000462 WO2003066056A1 (en) 2002-02-05 2003-02-04 Method of promoting neuronal growth

Publications (2)

Publication Number Publication Date
JP2005522432A true JP2005522432A (ja) 2005-07-28
JP2005522432A5 JP2005522432A5 (cg-RX-API-DMAC7.html) 2006-03-16

Family

ID=27736189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565480A Withdrawn JP2005522432A (ja) 2002-02-05 2003-02-04 ニューロン成長の促進方法

Country Status (5)

Country Link
US (1) US20070270432A1 (cg-RX-API-DMAC7.html)
EP (1) EP1471912A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005522432A (cg-RX-API-DMAC7.html)
AU (1) AU2003244452A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003066056A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
JP4571507B2 (ja) 2002-12-18 2010-10-27 スベン ライフ サイエンシズ リミティド セロトニン受容体親和性を有する四環系3−置換インドール
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
ATE430752T1 (de) 2004-01-02 2009-05-15 Suven Life Sciences Ltd Neue indenoä2,1-aüindene und isoindolä2,1-aüindol
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US7998981B2 (en) 2005-08-12 2011-08-16 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands
US7923566B2 (en) 2005-08-16 2011-04-12 Suven Life Sciences Limited Alternative process for the preparation of losartan
CN101553467B (zh) 2007-01-08 2011-12-07 苏文生命科学有限公司 5-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
AU2008246947B2 (en) 2007-05-03 2011-03-31 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands
CA2703157C (en) 2007-10-26 2013-02-05 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-ht6 ligands
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
MX2011002884A (es) 2008-09-17 2011-04-21 Suven Life Sciences Ltd Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6.
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
MX2012007783A (es) 2010-01-05 2012-10-03 Suven Life Sciences Ltd Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
KR101608499B1 (ko) 2013-10-08 2016-04-01 이화여자대학교 산학협력단 4-니트로인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Also Published As

Publication number Publication date
EP1471912A1 (en) 2004-11-03
US20070270432A1 (en) 2007-11-22
WO2003066056A1 (en) 2003-08-14
AU2003244452A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
US20070270432A1 (en) Novel Method
JP7082186B2 (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
JP2020143087A (ja) 障害を治療するための5ht作動薬
ME02495B (me) Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
KR20110114664A (ko) 자폐 스펙트럼 장애의 진단 및 치료
US20170224679A1 (en) Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN)
US12178811B2 (en) Methods of treating depressive disorders
US20250032503A1 (en) Use of aprepitant for treating alzheimer's disease
JP2016525547A (ja) 神経保護性の二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法
US20080027052A1 (en) Methods for treating cystic kidney disease
WO2023159238A1 (en) Mef2 transcriptional activators to treat neurologic conditions
JP7025094B2 (ja) ヘテロシクリデンアセトアミド誘導体含有医薬
JP6959371B2 (ja) 純粋な5−ht6受容体アンタゴニストの新たな使用
JP2002532545A (ja) 肉胞子虫、早生胞子虫及びトキソプラズマの故の疾患の処置のためのトリアジンオン化合物
KR20200043401A (ko) 신경 질환을 치료하기 위한 방법 및 조성물
CN120899704A (zh) 一种咔啉类化合物在制备抗抑郁药物中的应用
CN120865123A (zh) 一种苯磺酰胺类衍生物及其在制备抗抑郁药物中的应用
US11364231B2 (en) Methods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using YEL002/BCN057
AU2020218158B2 (en) Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
RU2354377C2 (ru) Способ лечения или предупреждения заболеваний центральной нервной системы с использованием соединений, обладающих селективностью в отношении альфа-3-субъединицы бензодиазепинового рецептора
AU2024200581A1 (en) Method of using human spheroids for drug discovery
US20240264149A1 (en) Composition for preventing or treating of ischemic cerebrovascular disease comprising an arginase-1 inhibitor
JP2024521282A (ja) 抗うつ・抗不安の置換桂皮アミド化合物
CN111084776A (zh) 匹立尼酸及其衍生物用于治疗和/或预防神经退行性疾病的用途
WO2012168411A1 (fr) Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060125

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100323